![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Clifford G, Franceschi S, Diaz M, Muñoz N, Villa L L. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24: S3/26–S3/34
- De Villiers E M, Fauquet C, Broker T R, Bernard H U, Zur Hausen H. Classification of papillomaviruses. Virology 2004; 324: 76–84
- Ferlay J, Bray F, Pisani P, Parkin D M. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase 5(2.0). IARC Press, Lyon 2004
- Giannini S, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24: 5937–5949
- Harper D M, Franco E L, Wheeler C M, Moscicki A B, Romanowski B, Roteli-Martins C M, , the HPV Vaccine Study Group, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247–1255
- Inglis S, Shaw A, Koenig S. HPV vaccines: commercial research and development. Vaccine 2006; 24: S3/99–S3/105
- Kitchener H C, Almonte M, Wheeler P, Desai M, Gilham C, Bailey A, , the ARTISTIC Trial Study Group, et al. British Journal of Cancer 2006; 95: 56–61
- Luesley D, Leeson S. Colposcopy and programme management. Guidelines for the NHS Cervical Screening Programme. 2004, NHSCSP, 20 April
- Madeleine M, Daling J, Carter J, Wipf G, Schwartz S, McKnight B, et al. Cofactors with human papillomavirus in a population-based study of vulvar cancer. Journal of the National Cancer Institute 1997; 89: 1516–1523
- Markowitz L E, Dunne E F, Saraiya M, Lawson H W, Chesson H, Unger E R, the Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56(RR-2)1–24
- Mercer C H, Wellings K, Macdowall W, Copas A J, McManus S, Erens B, et al. First sexual partnerships – age differences and their significance: empirical evidence from the 2000 British National Survey of Sexual Attitudes and Lifestyles (‘Natsal 2000’). Journal of Adolescent Health 2006; 39: 87–95
- Munoz N, Bosch F X, deSanjose S, Herrero R, Castellsaque X, Shah K V, et al. Epidemiological classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine 2003; 348: 518–527
- Peto J, Gilham C, Fletcher O, Matthews F E. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249–256
- Salisbury D. HPV vaccination announcement, CEM/CMO/2007/13. Immunisation and communicable disease team. Department of Health, London 2007
- Schiffman M, Herrero R, DeSalle R, Hildesheim A, Wacholder S, Rpdriguez A C, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76–84
- [The] FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high grade cervical lesions. New England Journal of Medicine 2007; 356: 1915–1927
- Walboomers J MM, Jacobs M V, Manos M M, Bosch F X, Kummer J A, Shah K V, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 1999; 189: 12–19